160 related articles for article (PubMed ID: 38306009)
1. Somatostatin receptor subtype 2A expression and genetics in 184 paragangliomas: a single center retrospective observational study.
Shen Y; Luo Y; Li M; Luo R; Chen L; Gao X; Jiang J; Liu Y; Lu Z; Zhang J
Endocrine; 2024 Feb; ():. PubMed ID: 38306009
[TBL] [Abstract][Full Text] [Related]
2. Increased SSTR2A and SSTR3 expression in succinate dehydrogenase-deficient pheochromocytomas and paragangliomas.
Elston MS; Meyer-Rochow GY; Conaglen HM; Clarkson A; Clifton-Bligh RJ; Conaglen JV; Gill AJ
Hum Pathol; 2015 Mar; 46(3):390-6. PubMed ID: 25554089
[TBL] [Abstract][Full Text] [Related]
3. Regulation of epinephrine biosynthesis in HRAS-mutant paragangliomas.
Li M; Richter S; Mohr H; Drukewitz S; Poser I; Stanke D; Calsina B; Martinez-Montes AM; Quinkler M; Timmers HJLM; Nölting S; Beuschlein F; Remde H; Opocher G; Rapizzi E; Pacak K; Pamporaki C; Robledo M; Liu L; Jiang J; Bornstein SR; Eisenhofer G; Fliedner SMJ; Bechmann N
Endocr Relat Cancer; 2023 Dec; 30(12):. PubMed ID: 37902037
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical distinction of paragangliomas from epithelial neuroendocrine tumors-gangliocytic duodenal and cauda equina paragangliomas align with epithelial neuroendocrine tumors.
Mamilla D; Manukyan I; Fetsch PA; Pacak K; Miettinen M
Hum Pathol; 2020 Sep; 103():72-82. PubMed ID: 32668278
[TBL] [Abstract][Full Text] [Related]
5. The mTORC1 Complex Is Significantly Overactivated in SDHX-Mutated Paragangliomas.
Oudijk L; Papathomas T; de Krijger R; Korpershoek E; Gimenez-Roqueplo AP; Favier J; Canu L; Mannelli M; Rapa I; Currás-Freixes M; Robledo M; Smid M; Papotti M; Volante M
Neuroendocrinology; 2017; 105(4):384-393. PubMed ID: 28122379
[TBL] [Abstract][Full Text] [Related]
6. A novel liquid biopsy (NETest) identifies paragangliomas and pheochromocytomas with high accuracy.
Pacak K; Kidd M; Meuter L; Modlin IM
Endocr Relat Cancer; 2021 Oct; 28(11):731-744. PubMed ID: 34515661
[TBL] [Abstract][Full Text] [Related]
7. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas.
Mete O; Asa SL; Gill AJ; Kimura N; de Krijger RR; Tischler A
Endocr Pathol; 2022 Mar; 33(1):90-114. PubMed ID: 35285002
[TBL] [Abstract][Full Text] [Related]
8. Analysis of somatostatin receptor 2A immunohistochemistry, RT-qPCR, and in vivo PET/CT data in patients with pancreatic neuroendocrine neoplasm.
Kaemmerer D; Wirtz RM; Fischer EK; Hommann M; Sänger J; Prasad V; Specht E; Baum RP; Schulz S; Lupp A
Pancreas; 2015 May; 44(4):648-54. PubMed ID: 25872131
[TBL] [Abstract][Full Text] [Related]
9. Variable somatostatin receptor subtype expression in 151 primary pheochromocytomas and paragangliomas.
Leijon H; Remes S; Hagström J; Louhimo J; Mäenpää H; Schalin-Jäntti C; Miettinen M; Haglund C; Arola J
Hum Pathol; 2019 Apr; 86():66-75. PubMed ID: 30529752
[TBL] [Abstract][Full Text] [Related]
10. Genotype and tumor locus determine expression profile of pseudohypoxic pheochromocytomas and paragangliomas.
Shankavaram U; Fliedner SM; Elkahloun AG; Barb JJ; Munson PJ; Huynh TT; Matro JC; Turkova H; Linehan WM; Timmers HJ; Tischler AS; Powers JF; de Krijger R; Baysal BE; Takacova M; Pastorekova S; Gius D; Lehnert H; Camphausen K; Pacak K
Neoplasia; 2013 Apr; 15(4):435-47. PubMed ID: 23555188
[TBL] [Abstract][Full Text] [Related]
11. In liver metastases from small intestinal neuroendocrine tumors, SSTR2A expression is heterogeneous.
Charoenpitakchai M; Liu E; Zhao Z; Koyama T; Huh WJ; Berlin J; Hande K; Walker R; Shi C
Virchows Arch; 2017 May; 470(5):545-552. PubMed ID: 28213807
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine tumors.
Kimura N; Pilichowska M; Date F; Kimura I; Schindler M
Clin Cancer Res; 1999 Nov; 5(11):3483-7. PubMed ID: 10589762
[TBL] [Abstract][Full Text] [Related]
13. Warburg effect's manifestation in aggressive pheochromocytomas and paragangliomas: insights from a mouse cell model applied to human tumor tissue.
Fliedner SM; Kaludercic N; Jiang XS; Hansikova H; Hajkova Z; Sladkova J; Limpuangthip A; Backlund PS; Wesley R; Martiniova L; Jochmanova I; Lendvai NK; Breza J; Yergey AL; Paolocci N; Tischler AS; Zeman J; Porter FD; Lehnert H; Pacak K
PLoS One; 2012; 7(7):e40949. PubMed ID: 22859959
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin receptor 2A in gliomas: Association with oligodendrogliomas and favourable outcome.
Kiviniemi A; Gardberg M; Kivinen K; Posti JP; Vuorinen V; Sipilä J; Rahi M; Sankinen M; Minn H
Oncotarget; 2017 Jul; 8(30):49123-49132. PubMed ID: 28467778
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine carcinoma of uterine cervix.
Kajiwara H; Hirabayashi K; Miyazawa M; Nakamura N; Hirasawa T; Muramatsu T; Mikami M; Yasuda M; Osamura RY
Arch Gynecol Obstet; 2009 Apr; 279(4):521-5. PubMed ID: 18726606
[TBL] [Abstract][Full Text] [Related]
16. The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma.
Fougner SL; Borota OC; Berg JP; Hald JK; Ramm-Pettersen J; Bollerslev J
Clin Endocrinol (Oxf); 2008 Mar; 68(3):458-65. PubMed ID: 17941904
[TBL] [Abstract][Full Text] [Related]
17. Expression of potential therapeutic target SSTR2a in primary and metastatic non-keratinizing nasopharyngeal carcinoma.
Tao L; Chen Y; Shi X; Yu G; Yin W; Huang Y
Virchows Arch; 2020 Oct; 477(4):573-579. PubMed ID: 32328798
[TBL] [Abstract][Full Text] [Related]
18. SDHC Promoter Methylation, a Novel Pathogenic Mechanism in Parasympathetic Paragangliomas.
Bernardo-Castiñeira C; Valdés N; Sierra MI; Sáenz-de-Santa-María I; Bayón GF; Perez RF; Fernández AF; Fraga MF; Astudillo A; Menéndez R; Fernández B; Del Olmo M; Suarez C; Chiara MD
J Clin Endocrinol Metab; 2018 Jan; 103(1):295-305. PubMed ID: 29126304
[TBL] [Abstract][Full Text] [Related]
19. Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patients.
Currás-Freixes M; Inglada-Pérez L; Mancikova V; Montero-Conde C; Letón R; Comino-Méndez I; Apellániz-Ruiz M; Sánchez-Barroso L; Aguirre Sánchez-Covisa M; Alcázar V; Aller J; Álvarez-Escolá C; Andía-Melero VM; Azriel-Mira S; Calatayud-Gutiérrez M; Díaz JÁ; Díez-Hernández A; Lamas-Oliveira C; Marazuela M; Matias-Guiu X; Meoro-Avilés A; Patiño-García A; Pedrinaci S; Riesco-Eizaguirre G; Sábado-Álvarez C; Sáez-Villaverde R; Sainz de Los Terreros A; Sanz Guadarrama Ó; Sastre-Marcos J; Scolá-Yurrita B; Segura-Huerta Á; Serrano-Corredor Mde L; Villar-Vicente MR; Rodríguez-Antona C; Korpershoek E; Cascón A; Robledo M
J Med Genet; 2015 Oct; 52(10):647-56. PubMed ID: 26269449
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin receptor SSTR2A and SSTR5 expression in neuroendocrine breast cancer.
Terlević R; Perić Balja M; Tomas D; Skenderi F; Krušlin B; Vranic S; Demirović A
Ann Diagn Pathol; 2019 Feb; 38():62-66. PubMed ID: 30476894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
